Efficacy and safety of osilodrostat in patients with ectopic Cushing´s syndrome. a real-world study in Spain
Overall, osilodrostat controls hypercortisolism in approximately 90% of the patients with ECS and severe hypercortisolism and with normalization of UFC in 40% of cases after just 4 weeks of treatment. Therefore, osilodrostat should be considered as first-line treatment in patients with ECS, especially in patients with severe hypercortisolism.
Authors
- Cristina Novo‐Rodríguez (ORCID: https://orcid.org/0000-0002-7765-6695)
- Rocío Villar‐Taibo (ORCID: https://orcid.org/0000-0001-6022-2375)
- Luis Candil Valero
- Fernando Cordido (ORCID: https://orcid.org/0000-0003-3528-8174)
- Andrés Cardona (ORCID: https://orcid.org/0000-0002-8318-8744)
- Rosa Cámara (ORCID: https://orcid.org/0000-0002-3289-3400)
- Anna Aulinas (ORCID: https://orcid.org/0000-0002-1205-7114)
- Laura González Fernández (ORCID: https://orcid.org/0000-0003-4096-8115)
- Ana Irigaray (ORCID: https://orcid.org/0000-0002-5307-1991)
- Andreu Simó-Servat (ORCID: https://orcid.org/0000-0002-1092-1327)
- Pedro Iglesias (ORCID: https://orcid.org/0000-0003-0126-1985)
- Marta Araujo‐Castro (ORCID: https://orcid.org/0000-0002-0519-0072)
- Fernando Guerrero‐Pérez (ORCID: https://orcid.org/0000-0002-4165-4356)
- Ana Castro (ORCID: https://orcid.org/0000-0001-8328-2805)
- Alfonso Soto‐Moreno (ORCID: https://orcid.org/0000-0002-2734-7077)
- Ignacio Bernabéu (ORCID: https://orcid.org/0000-0001-8421-7394)
- Inmaculada González Molero
- Rogelio García-Centeno
- Betina Biagetti (ORCID: https://orcid.org/0000-0002-8837-4343)
- Felicia A. Hanzu (ORCID: https://orcid.org/0000-0002-2399-4023)
- María Calatayud (ORCID: https://orcid.org/0000-0002-6737-7289)
- Pablo Abellán Galiana (ORCID: https://orcid.org/0000-0003-1221-3946)
- Eider Pascual‐Corrales (ORCID: https://orcid.org/0000-0003-2378-2335)
- Carmen Tenorio-Jiménez (ORCID: https://orcid.org/0000-0002-1773-6036)
- Carmen Fajardo (ORCID: https://orcid.org/0000-0002-0784-0761)
- María Dolores Moure Rodríguez
- María Dolores Ollero García
- Miguel Paja (ORCID: https://orcid.org/0000-0001-7803-089X)
- Paola Gracia
- Jessica Goi
Institutions
- Universidade da Coruña (ES)
- University of the Basque Country (ES)
- Instituto Cajal (ES)
- Hospital de Sant Pau (ES)
- Bellvitge University Hospital (ES)
- ProMedica Toledo Hospital (US)
- Hospital General Universitario Gregorio Marañón (ES)
- Hospital Universitari i Politècnic La Fe (ES)
- Hospital de Basurto (ES)
- Hospital Terrassa (ES)
- Hospital de La Ribera (ES)
- Complejo Hospitalario Universitario de Santiago (ES)
- Complejo Hospitalario de Navarra (ES)
- Hospital Universitario 12 De Octubre (ES)
- Hospital Royo Villanova (ES)
- Hospital Universitario Puerta de Hierro Majadahonda (ES)
- Hospital Regional Universitario de Málaga (ES)
- Hospital Clínic de Barcelona (ES)
- Hospital Universitario Virgen de las Nieves (ES)
- Leitat Technological Center (ES)
- Hospital General Universitari de Castelló (ES)
- Instituto Ramón y Cajal de Investigación Sanitaria (ES)
- Vall d'Hebron Hospital Universitari (ES)
- Hospital de Cruces (ES)
- Complexo Hospitalario Universitario A Coruña (ES)
- Hospital Universitario Virgen del Rocío (ES)
- Hospital Universitario Ramón y Cajal (ES)
- Complejo Hospitalario Universitario de Toledo (ES)
- Instituto de Investigación Sanitaria La Fe (ES)
- Universidad de Navarra (ES)
Publication Details
- Journal
- Journal of Endocrinological Investigation
- Published
- 2025-12-03
- DOI
- https://doi.org/10.1007/s40618-025-02769-0
- Citations
- 2
- Primary Topic
- Adrenal Hormones and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 2.59